Glaxosmithkline Share News (GSK)

London close: Stocks close lower on UK deflation, weak Chinese trade data

(ShareCast News) - The FTSE 100 ended down 28.90 points to 6,342.28 on Tuesday as September data showed the UK experienced deflation and China's exports and imports declined. The Office for National Statistics said the UK consumer price index fell 0.1% year-on-year last month, compared to analysts'

FTSE 100 movers: SAB surges on AB InBev agreement; Royal Mail slumps

(ShareCast News) - London's FTSE 100 was down 1.1% by mid afternoon at 6,304.21 as uninspiring Chinese trade figures and UK inflation data weighed on investors' minds. London-listed brewer SABMiller surged after it agreed in principle to a possible £44 per share takeover offer from Belgium-based Anh

JPMorgan ups Glaxo to 'neutral', says consensus now looks achievable

(ShareCast News) - JPMorgan Cazenove upgraded GlaxoSmithKline to 'neutral' from 'underweight' and lifted the price target to 1,370p from 1,320p. The bank noted that medium-term consensus earnings per share estimates have fallen 15-18% year-to-date and expectations now look achievable, with downgrade

Tuesday broker round-up

(ShareCast News) - Ladbrokes: Citigroup upgrades to neutral, raises target price to 110.00p. Jupiter Fund Management: RBC Capital Markets upgrades to outperform, bumps up target price to 475.00p. Jefferies reiterates to buy, lifts target price to 493.00p. Glaxosmithkline: JP Morgan Cazenove upgrade

WINNERS & LOSERS SUMMARY: SABMiller Accepts Improved AB InBev Offer

BROKER RATINGS SUMMARY: Citi Cuts AB Foods As UBS Raises Smiths Group

LONDON MARKET OPEN: SABMiller Rises But FTSE 100 Hit By China Data

LONDON BRIEFING: SABMiller Succumbs To AB InBev To Create Beer Giant

BUZZ-GlaxoSmithKline PLC: JP Morgan says bear thesis played out, upgrades to "neutral"

(Updates RIC in 1st bullet) ** JP Morgan changes prior call on GlaxoSmithKline and lifts British drugmaker's stock to "neutral" ** Earnings expectations now look achievable, pipeline review suggests upcoming R&D day has positive risk/reward and stock's 6-pct dividend yield provides

BUZZ-GlaxoSmithKline PLC: JP Morgan says bear thesis played out, upgrades to "neutral"

** JP Morgan changes prior call on GlaxoSmithKline (GSK.N> and lifts British drugmaker's stock to "neutral" ** Earnings expectations now look achievable, pipeline review suggests upcoming R&D day has positive risk/reward and stock's 6-pct dividend yield provides near-term support with a cu

BROKER RATINGS SUMMARY: Investec Cuts Standard Chartered To Hold

Glaxo makes European application for antiseptic gel

(ShareCast News) - GlaxoSmithKline has submitted a regulatory application to the European Medicines Agency for its antiseptic chlorhexidine gel for the prevention of umbilical cord infections in newborn babies. Glaxo said the EMA has granted the application accelerated assessment, a process open to

Glaxo Submits European Regulatory Application For Chlorhexidine Gel

UPDATE 2-J&J starts vaccine trial in Sierra Leone, even as Ebola fades

* Trial to test safety and immunogenicity of Ebola vaccine * J&J working with Bavarian Nordic on prime-boost vaccine (Adds executive comment, link to story on Ebola nurse) By Ben Hirschler Oct 9 (Reuters) - Johnson & Johnson has begun a clinical trial of a two-shot Ebola vacci

UPDATE 1-J&J starts clinical trial of Ebola vaccine in Sierra Leone

(Adds more detail on vaccines) Oct 9 (Reuters) - Johnson & Johnson has begun a clinical trial of a two-shot Ebola vaccine in Sierra Leone, underlining its determination to push ahead with development, even as the epidemic fades out West Africa. The new study will investigate the exper